Neuronetics, Inc. (STIM) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
3.09
↑+28% vs avg
5yr avg: 2.42
30Y Low1.3·High8.2
ROE
↓
-134.4%
↑-52% vs avg
5yr avg: -88.3%
30Y Low-134%·High-34%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
STIM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Neuronetics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $86M | $91M | $51M | $83M | $185M | $114M | $209M | $83M | $173M | — | — |
| Enterprise Value | $142M | $147M | $114M | $86M | $154M | $59M | $199M | $41M | $99M | — | — |
| P/E Ratio → | -2.08 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.57 | 0.61 | 0.68 | 1.16 | 2.83 | 2.05 | 4.25 | 1.32 | 3.28 | — | — |
| P/B Ratio | 3.09 | 3.47 | 1.61 | 2.43 | 3.24 | 1.33 | 8.21 | 1.72 | 2.44 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
STIM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.99 | 1.53 | 1.20 | 2.36 | 1.07 | 4.03 | 0.66 | 1.88 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
STIM Profitability
Margins and return-on-capital ratios measuring operating efficiency
Neuronetics, Inc. earns an operating margin of -21.1%. Operating margins have expanded from -42.8% to -21.1% over the past 3 years, signaling improving operational efficiency. A negative ROE of -134.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 48.5% | 48.5% | 72.3% | 72.5% | 76.3% | 78.9% | 76.5% | 75.4% | 76.4% | 76.2% | 80.7% |
| Operating Margin | -21.1% | -21.1% | -46.2% | -42.8% | -53.8% | -49.8% | -45.3% | -43.0% | -37.6% | -33.7% | -27.3% |
| Net Profit Margin | -26.1% | -26.1% | -58.4% | -42.3% | -57.0% | -56.4% | -55.7% | -46.4% | -45.7% | -39.7% | -32.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -134.4% | -134.4% | -132.5% | -66.2% | -52.3% | -56.4% | -74.9% | -48.9% | -33.9% | — | — |
| ROA | -27.6% | -27.6% | -34.0% | -25.9% | -28.8% | -28.4% | -30.7% | -26.7% | -30.9% | -50.4% | -45.3% |
| ROIC | -26.6% | -26.6% | -39.3% | -72.2% | -92.3% | -91.0% | -156.8% | -1215.3% | — | — | — |
| ROCE | -28.5% | -28.5% | -33.6% | -34.0% | -33.6% | -28.9% | -32.5% | -30.6% | -30.4% | -70.9% | -81.5% |
STIM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $56M ($90M total debt minus $34M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.44 | 3.44 | 2.60 | 1.83 | 0.70 | 0.46 | 1.50 | 0.72 | 0.43 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 2.14 | 1.99 | 0.08 | -0.54 | -0.64 | -0.42 | -0.86 | -1.04 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -3.74 | -3.74 | -5.00 | -4.57 | -9.34 | -8.45 | -5.93 | -7.67 | -5.53 | -4.72 | -5.12 |
STIM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Neuronetics, Inc.'s current ratio of 2.02x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.73x to 2.02x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.02 | 2.02 | 1.86 | 4.73 | 2.98 | 7.34 | 4.75 | 3.19 | 8.44 | 3.09 | 1.72 |
| Quick Ratio | 1.87 | 1.87 | 1.72 | 4.33 | 2.71 | 6.93 | 4.48 | 3.09 | 8.26 | 2.88 | 1.59 |
| Cash Ratio | 1.13 | 1.13 | 0.63 | 3.06 | 2.17 | 6.14 | 3.72 | 2.77 | 7.71 | 2.43 | 1.28 |
| Asset Turnover | — | 1.05 | 0.53 | 0.62 | 0.56 | 0.39 | 0.63 | 0.63 | 0.45 | 1.04 | 1.38 |
| Inventory Turnover | 17.76 | 17.76 | 4.88 | 2.43 | 1.74 | 1.78 | 3.11 | 5.55 | 5.12 | 3.90 | 3.90 |
| Days Sales Outstanding | — | 41.34 | 118.36 | 91.26 | 77.36 | 51.34 | 53.11 | 38.27 | 38.87 | 38.52 | 38.14 |
STIM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Neuronetics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $66M | $32M | $29M | $27M | $25M | $19M | $18M | $9M | $11220 | $11220 |
Peer Comparison
Compare STIM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 STIMYou | $86M | -2.1 | — | — | 48.5% | -21.1% | -134.4% | -26.6% | — |
 ELMD | $320M | 45.0 | 27.6 | 28.9 | 78.1% | 15.4% | 17.2% | 26.1% | 0.0 |
 NVCR | $2B | -11.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ABSI | $1B | -8.8 | — | — | -319.4% | -4454.2% | -62.5% | -58.0% | — |
 LIVN | $4B | -17.6 | 17.2 | 24.9 | 67.7% | 14.4% | -19.2% | 11.5% | 2.0 |
 INVA | $2B | 6.8 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 GKOS | $8B | -39.8 | — | — | 77.5% | -17.1% | -26.4% | -9.2% | — |
 ABT | $154B | 11.6 | 16.1 | 24.2 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 MDT | $102B | 22.0 | 14.5 | 19.6 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 BSX | $67B | 23.3 | 20.8 | 18.4 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 SYK | $118B | 36.6 | 21.2 | 27.5 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
STIM — Frequently Asked Questions
Quick answers to the most common questions about buying STIM stock.
What is Neuronetics, Inc.'s P/E ratio?
Neuronetics, Inc.'s current P/E ratio is -2.1x. This places it at the 50th percentile of its historical range.
What is Neuronetics, Inc.'s ROE?
Neuronetics, Inc.'s return on equity (ROE) is -134.4%. The historical average is -74.9%.
Is STIM stock overvalued?
Based on historical data, Neuronetics, Inc. is trading at a P/E of -2.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Neuronetics, Inc.'s profit margins?
Neuronetics, Inc. has 48.5% gross margin and -21.1% operating margin.